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Abstract
Several tumors can exist as multiple lesions within a tissue. The lesions may either arise
independently, or they may be monoclonal. The importance of multiple lesions for tumor staging,
progression, and treatment is subject to debate. Here we use mathematical models to analyze the
emergence of multiple, clonally related lesions within a single tissue. We refer to them as multi-
focal cancers. We find that multifocal cancers can arise through a dynamical interplay between
tumor promoting and inhibiting factors. This requires that tumor promoters act locally, while
tumor inhibitors act over a longer range. An example of such factors may be angiogenesis
promoters and inhibitors. The model further suggests that multifocal cancers represent an
intermediate stage in cancer progression as the tumor evolves away from inhibition and towards
promotion. Different patterns of progression can be distinguished: (i) If tumor inhibition is strong,
the initial growth occurs as a unifocal and self contained lesion; progression occurs through
bifurcation of the lesion and this gives rise to multiple lesions. As the tumor continues to evolve
and pushes the balance between inhibition and promotion further towards promotion, the multiple
lesions eventually give rise to a single large mass which can invade the entire tissue. (ii) If tumor
inhibition is weaker upon initiation, growth can occur as a single lesion without the occurrence of
multiple lesions, until the entire tissue is invaded. The model suggests that the sum of the tumor
sizes across all lesions is the best characteristic which correlates with the stage and metastatic
potential of the tumor.
1 Introduction
The occurrence of multiple lesions is observed in a variety
of cancers. That is, not one, but several lesions are
observed within a given tissue. Multiple lesions can occur
by two basic mechanisms [1-5]. Either they originate inde-
pendently by separate carcinogenic events, or they are
generated by a single transformation event (monoclonal
origin). Sometimes, the term "multicen-tric cancers" is
used to describe the occurrence of clonally unrelated
lesions, while the term "multifocal" refers to a mono-
clonal origin [6]. Clinically, it is important to determine
the nature of multiple lesions. The occurrence of multiple
lesions can be indicative of a familial cancer, especially if
they occur at a relatively young age. Examples are familial
adenomatous poliposis (FAP) in the colon, and familial
retinoblastoma [7]. The genetic predisposition of such
individuals renders multiple independent carcinogenic
events likely. Alternatively, multiple independent lesions
can be the result of a large area of tissue which has been
altered and is prone to the development of cancer, such as
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Barrett's esophagus [8], or by other mechanisms which are
not yet under-stood. On the other hand, genetic analysis
has indicated that multiple lesions in several cases have a
monoclonal origin [8-18]. Examples are mammary carci-
noma, gliomas, renal cell carcinoma, hepatocellular carci-
noma, and esophageal adenocarcinoma.
In this paper we focus on multiple lesions with a mono-
clonal origin. We will refer to them as "multifocal" can-
cers. The mechanism by which such multifocal cancers are
generated, and their relation to the stage and metastatic
potential of the cancer, are not fully understood [19]. Yet,
this understanding is important for decisions regarding
treatment and surgery. Here, we report that multifocal
cancers can be generated through the dynamical interplay
between tumor promoting and inhibiting factors. Mathe-
matical modeling indicates that somatic evolution away
from tumor inhibition and towards tumor promotion
results in the transition from a small contained tumor, to
multi-focal tumors, and finally to a large tumor mass
within a tissue. Multifocal tumors therefore represent an
intermediate stage in tumor progression. Several studies
have identified tumor promoting and inhibiting factors,
produced either by the tumor cells themselves, or by sur-
rounding tissue cells. An obvious example is angiogenesis
inhibition and promotion, where simple mutations can
change the balance away from inhibition and in favor of
promotion [20,21]. Other inhibiting factors which are not
related to angiogenesis have also been observed, although
their exact identity and function remain unknown [22].
2 Results
We start with a simple model which describes tumor
growth in relation to the production of promoters and
inhibitors. We then extend this model to describe the
local spread of cancer cells across space (tissue), and
examine somatic evolution of cells away from tumor inhi-
bition and towards promotion.
The basic model
We consider a basic mathematical model which describes
the growth of a cancer cell population, assuming that the
amount of blood supply influences the rate of cell divi-
sion. The model includes three variables: the population
of cancer cells, C; promoters, P; and inhibitors, I. It is
assumed that both promoters and inhibitors can be pro-
duced by cancer cells. In addition, inhibitors may be pro-
duced by healthy tissue. The model is given by the
following set of differential equations which describe can-
cer growth as a function of time,
The equations are based on a previous study [23]. The
population of cancer cells grows with a rate r. Growth is
assumed to be density dependent and saturates if the pop-
ulation of cancer cells becomes large (expressed in the
parameter ε). In addition, the growth rate of the cancer
cells depends on the balance between promoters and
inhibitors, expressed as P/(I + 1). The higher the level of
promoters relative to inhibitors, the faster the growth rate
of the cancer cell population. If the level of promoters is
zero, or the balance between promoters and inhibitors in
heavily in favor of inhibitors, the cancer cells cannot grow
and remain dormant [24-26]. Cancer cells are assumed to
die at a rate δ. Promoters are produced by cancer cells at a
rate ap and decay at a rate bp. Inhibitors are produced by
cancer cells at a rate aI and decay at a rate bI. In addition,
the model allows for production of inhibitors by normal
tissue at a rate ξ.
Insights from the model
The analysis of the model above is presented in detail in
the Materials and Methods section. It suggests the follow-
ing patterns. There are two outcomes. (i) The cancer cells
cannot grow and consequently go extinct.That is, C = 0, P
= 0 and I = 0. The cancer goes extinct in the model because
we only consider cells which require the presence of pro-
moters for division. If the level of promoters is not suffi-
cient, the rate of cell death is larger than the rate of cell
division. In reality, however, it is possible that a small
population of non-angiogenic tumor cells survives. Here,
we omit this for simplicity. (ii) The population of cancer
cells grows to significant levels, that is, C = .
How do the parameter values influence the outcome of
cancer growth? The cancer extinction outcome is always
stable. The reason is as follows. The cancer cells require
promoters to grow. The promoters, however, are pro-
duced by the cancer cells themselves. If we start with a rel-
atively low initial number of cancer cells, this small
population cannot produce enough promoters to over-
come the presence of inhibitors. Consequently, the cancer
fails to grow and goes extinct. This outcome is always a
possibility, regardless of the parameter values. Significant
cancer growth can be observed if the intrinsic growth rate,
r, lies above a threshold relative to the death rate of the
cells, δ, and degree of tumor cell inhibition (ap and bp rel-
ative to aI and bI, i.e. the production and decay rates of
promoters and inhibitors, respectively). The exact condi-
tion is given by (9). In this case, the outcome is either fail-
ure of cancer growth, or successful growth to large
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numbers. Which outcome is achieved depends on the ini-
tial conditions. Successful growth is only observed if the
initial number of cancer cells lies above a threshold. Then,
enough promoters are initially produced to overcome
inhibition. This provides an important barrier to the suc-
cessful growth of cancers. It could explain why it is diffi-
cult for cancers to escape angiogenesis inhibition, and
why autopsies often reveal the existence of multiple small,
non-pathogenic tumors which have failed to progress
[27].
Modeling the spread of tumors across space
In this section, we introduce space into the above
described model. We consider a one-dimensional space
along which tumor cells can migrate. The model is formu-
lated as a set of partial differential equations and is written
as follows,
The model assumes that tumor cells can migrate, and this
is described by the diffusion coefficient Dc. Inhibitors can
also diffuse across space, and this is described by the dif-
fusion coefficient DI. It is generally thought that inhibitors
act over a longer range, while promoters act locally
[21,24]. Therefore, we make the extreme assumption that
promoters do not diffuse. Again, we ignore for simplicity
the production of inhibitors by healthy tissue, ξ. As
before, numerical simulations indicate that results are not
changed qualitatively by this simplification. As men-
tioned above, the model considers tumor spread across
space. It is important to point out that we do not consider
long-range metastatic spread. Instead, we consider local
spread of a tumor within a tissue, such as the breast, liver,
brain, or esophagus.
Here we investigate the process of tumor growth and pro-
gression in relation to the degree of inhibition and pro-
motion. A mathematical analysis is presented in the
Materials and Methods section. Here we present biologi-
cal insights and results of numerical simulations.
Insights from the spatial model
We start with a scenario where the degree of inhibition is
much larger than the degree of promotion (aI/bI >>ap/bp).
This corresponds to the early stages when the tumor is
generated. We then investigate how tumor growth
changes as the degree of inhibition is reduced relative to
the level of promotion (i.e. the value of aI/bI is reduced).
We consider the following parameter regions (Figure 1).
1. If the degree of inhibition is strong and lies above a
threshold, growth of the cancer cells to higher levels does
not occur (not shown). Only a small number of cells
which do not require promotion for survival would
remain.
2. If the degree of inhibition is weaker, the cancer cells can
grow. The spread across space is, however, self-limited
(Figure 1a). The cancer cells migrate across space. The
inhibitors produced by the cancer cells also spread across
space, while the promoters do not. Therefore, as the can-
cer cells migrate, they enter regions of the tissue where the
balance of inhibitors to promoters is heavily in favor of
inhibitors. Consequently, these cells cannot grow within
the space. They remain dormant and may eventually die.
In biological terms, this corresponds to a single coherent
but self-limited lesion (uni-focal). Note that this does not
mean that it is in principle impossible to generate more
lesions. It means that the space between lesions is bigger
than the space provided for cancer growth within the
tissue.
3. As the production of inhibitors is further reduced, we
enter another parameter region. Now fewer inhibitors dif-
fuse across space. We observe that multiple lesions or foci
are formed (Figure 1b). They are separated by tissue space
which does not contain any tumor cells. The separate
lesions produce some inhibitors, and they diffuse across
space. This explains the absence of tumor cells between
lesions. Because the production of inhibitors is weakened,
however, tumor growth is only inhibited in a certain area
around the lesion, and not across the whole space. How
many lesions are found within a tissue depends on the
parameters in the model, in particular on the relative
strength of inhibition and promotion (Figure 1b and 1c).
The stronger the degree of inhibition, the larger the space
between lesions, and the fewer lesions we expect. The
weaker the degree of inhibition, the smaller the space
between lesions, and the larger the expected number of
lesions. In biological terms, this corresponds to the occur-
rence of multi-focal cancers.
4. If the degree of inhibition is further reduced and lies
below a threshold, spread of inhibitors is sufficiently
diminished such that the tumor cells can invade the entire
space and tissue (Figure 1d). In biological terms, this cor-
responds to the most extensive tumor growth possible
within a tissue.
In summary, as the relative degree of inhibition is
reduced, the patterns of tumor growth change from
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Outcome of the spatial model depending on the relative balance of promoters and inhibitors, captured in the variable ai Figure 1
Outcome of the spatial model depending on the relative balance of promoters and inhibitors, captured in the variable ai. 
Parameters were chosen as follows: r = 1; δ = 0.1; aP = 5; bP = 0.1; bI = 0.01; DC = 0.00001; DI = 0.001; L = 2. For (a) aI = 3, (b), 
aI = 2, (c), aI = 1, (d) aI = 0.1.
0
2
4
6
8
10
02 04 06 08 0 1 0 0
0
2
4
6
8
10
02 04 06 08 0 1 0 0
0
5
10
15
02 04 06 08 0 1 0 0
0
10
20
30
40
50
02 04 06 08 0 1 0 0
Space (arbitrary units)
N
u
m
b
e
r
 
o
f
 
t
u
m
o
r
 
c
e
l
l
s
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
(a)
(b)
(c)
(d)Journal of Carcinogenesis 2004, 3:13 http://www.carcinogenesis.com/content/3/1/13
Page 5 of 13
(page number not for citation purposes)
absence of significant growth, to a single self-limited
tumor, to the occurrence of multiple foci, and to the max-
imal invasion of the tissue by tumor cells. Multi-focal can-
cers may arise through the dynamical interplay between
long range inhibition and local promotion. The following
section will examine this in the light of somatic evolution.
3 Discussion
We have shown how the pattern of cancer growth can
depend on the relative balance of promoters and inhibi-
tors. Here we consider these results in the context of
somatic evolution, and suggest some clinical
implications.
Somatic cancer evolution and progression
At early stages of cancer progression, the balance between
inhibitors and promoters is in favor of inhibition. Inhibi-
tors are likely to be produced by healthy cells (e.g. in the
context of angiogenesis), and they are more abundant
than an initiating population of transformed cells. In the
context of angiogenesis, specific mutations have been
shown to result in the enhanced production of promoters
or reduced production of inhibitors in cancer cells. Our
model has shown that such mutants have to be produced
at a relatively high frequency, so that a sufficient number
of promoting cells are present in order to ensure that
enough promoters are produced to overcome the effect of
inhibition.
Once the promoting cells have succeeded to expand, can-
cer progression can occur in a variety of ways according to
the model. How the cancer progresses depends on how
much the balance between promotion and inhibition has
been shifted in favor of promotion. We distinguish
between three possibilities (Figures 2, 3 &4).
(i) The balance between inhibition and promotion has
been shifted only slightly in favor of promotion, such that
self-limited growth of the cancer is observed (Figure 2).
That is, we observe a single lesion which can grow to a cer-
tain size but which is limited in the spread through the tis-
sue. In order to progress further towards the occurrence of
multiple lesions or towards more extensive invasion of
the tissue, further mutants have to be generated which are
characterized by enhanced production of promoters or by
reduced production of inhibitors. This introduces a new
problem: such a mutant will not have a selective advan-
tage, but is selectively neutral relative to the other cells.
This is because the promoters and inhibitors secreted
from one cell affect the whole population of cells. If the
mutant produces more promoters, not only the mutant,
but the entire population of tumor cells benefits. This
means that a mutant characterized by enhanced produc-
tion of promoters will not invade the tumor cell popula-
tion. Instead, we observe genetic drift which is stochastic
and not described by the equations considered here. The
model does, however, suggest the following (Figure 2): if
the population of mutant cells remains below a given
threshold relative to the rest of the tumor cells, it will not
alter the growth pattern. If the population of mutant cells
grows beyond a threshold relative to the rest of the tumor
cells, it can change the pattern of cancer growth, even if
the mutants do not become fixed in the population (Fig-
ure 2). The change can either be the generation of multi-
ple lesions, or invasion of the whole tissue, depending on
the amount by which the level of promotion has been
enhanced by the mutant cell population. The chances that
the mutant cell population drifts to levels high enough to
cause such a change in tumor growth depend on the pop-
ulation size of the lesion. The larger the number of tumor
cells, the lower the chance that the relative population size
of the mutants can cross this threshold. If this cannot
occur, further cancer progression not only requires the
generation of a mutation which enhances the level of pro-
motion, but an additional mutation which gives the pro-
moter mutant a selective advantage over the rest of the cell
population. That is, in addition to the mutation which
shifts the balance in favor of promotion, a mutation is
required either in an oncogene or a tumor suppressor gene
so that the mutant can grow to sufficiently high numbers
or fixation.
(ii) The first mutation shifts the balance between promot-
ers and inhibitors to a lager extent which is sufficient to
result in the generation of multiple lesions (Figure 3). The
multiple lesions do not, however, occur immediately.
First, the tumor grows as a single and self limited lesion
(Figure 3). Over time, this lesion bifurcates to give rise to
two lesions, or further lesions if the degree of promotion
is large enough relative to the degree of inhibition (Figure
3). The temporal sequence from a single and self-control-
led lesion to the occurrence of multiple lesions is the same
as in the previous case. But in contrast to the previous
case, no further mutations are required. This is because
multiple foci arise from the split and migration of a single
lesion. The number of foci that form depends on the exact
degree of promotion which was achieved by the initial
mutation. The higher the degree of promotion, the larger
the number of lesions. Growth beyond this number of
lesions (which will eventually result in maximal invasion)
then requires higher levels of promotion. This is in turn
achieved by further mutational events according to the
same principles as described in the previous section.
(iii) Finally, assume that the initial mutation shifts the
balance so much in favor of promotion that maximal
invasion of the tissue is possible (Figure 4). Now we
observe cancer progression without the generation of
multiple foci. Instead, a relatively small single lesion
expands in space until all the tissue has been invaded.Journal of Carcinogenesis 2004, 3:13 http://www.carcinogenesis.com/content/3/1/13
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Tumor progression if the initial mutant cell line has only shifted the balance between promoters and inhibitors slightly in favor  of promotion Figure 2
Tumor progression if the initial mutant cell line has only shifted the balance between promoters and inhibitors slightly in favor 
of promotion. This cell line can only give rise to self limited growth. Further tumor growth requires the generation of further 
mutants. The new mutant in the simulation is depicted by the dashed line. Parameters were chosen as follows: r = 1; δ = 0.1; aP 
= 5; bP = 0.1; aI = 3; bI = 0.01; Dc = 0.00001; DI = 0.001; L = 2. For mutant: aI = 0.5; aP = 20.
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Tumor progression if the initial mutant cell line has shifted the balance between promoters and inhibitors more substantially  towards promotion Figure 3
Tumor progression if the initial mutant cell line has shifted the balance between promoters and inhibitors more substantially 
towards promotion. Now, multiple foci can develop without the need for further mutations. The multiple foci develop, how-
ever, by first generating a single lesion which subsequently splits to give rise to two lesions during the natural growth process. 
Parameters were chosen as follows: r = 1; δ = 0.1; aP = 5; bP = 0.1; aI = 1; bI = 0.01; DC = 0.00001; DI = 0.001; L = 2.
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Tumor progression if the initial cell line has largely escaped inhibition, and promotion is the dominant force Figure 4
Tumor progression if the initial cell line has largely escaped inhibition, and promotion is the dominant force. Now the tumor 
grows in space as a single lesion until the whole tissue is invaded. Parameters were chosen as follows; r = 1; δ = 0.1; aP = 5; bP 
= 0.1; aI = 0.1; bI = 0.01; DC = 0.00001; DI = 0.001; L = 2.
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In summary, the model predicts different modes of cancer
progression in relation to the evolution away from tumor
inhibition and towards promotion. A single cancer lesion
may spread across the tissue without the occurrence of
multiple lesions. Alternatively, the cancer can first grow as
a single, self-contained lesion. This can then bifurcate to
give rise to multiple foci, either as a result of additional
mutations, or as a result of the natural pathway by which
multiple foci are generated, depending on the degree of
tumor promotion conferred by the initial mutation. Fur-
ther evolutionary events can then induce the multiple foci
to become a single, maximally invasive mass. The occur-
rence of multiple foci therefore represents an intermediate
stage in tumor progression towards malignancy.
Clinical implications
The models discussed here show that multiple foci with a
monoclonal origin can develop through a dynamical
interplay between tumor promoters and inhibitors. The
cancer can only grow to high loads as a single mass if it has
largely escaped all inhibitory effects. Otherwise, the can-
cer is likely to grow via the generation of a relatively small
and self limited tumor which then bifurcates into multi-
ple foci until it finally invades the entire tissue. The occur-
rence of multiple foci is therefore an intermediate stage in
cancer progression. The higher the number of foci, the fur-
ther advanced the stage of cancer progression.
A clinically important step in carcinogenesis is the process
of metastasis. That is, the spread of tumor cells to the
lymph node, entry into the blood supply, and the spread
to other tissues. Various studies have investigated the met-
astatic potential of multi-focal compared to uni-focal can-
cers [19,28,29]. In uni-focal cancers, tumor size has been
found to be a predictor of metastatic potential. For staging
multi-focal breast carcinomas, it has been suggested to use
the diameter of the largest tumor only [19]. This, however,
assumes that the other foci do not significantly contribute
to tumor progression. According to our arguments, this
would under-stage the cancer. According to the model, the
number of foci correlates with the stage of the disease.
This has also been concluded in clinical studies, and is
supported by data which show reduced patient survival
with multi-focal compared to uni-focal cancers [19].
Moreover, because our model suggests that multi-focality
can occur as a result of reduced tumor cell inhibition, suc-
cessful metastatic growth might be easier to achieve.
Although under debate, some data suggest that inhibitors
produced by the primary tumor can prevent metastatic
cells from growing [24]. If multi-focality correlates with
reduced inhibition, then it could also correlate with an
increased chance that metastatic cells grow and do not
remain dormant.
Further, it is important to note that studies which aim to
assess the correlation between multi-focality and meta-
static potential should not only concentrate on the
number of foci, but also on the size of the foci. As we have
shown with the model, cancer progression might start
with a small single lesion which can be considered uni-
focal. It can then bifurcate to give rise to multiple foci, and
finally spread through the entire tissue. When such spread
occurs, the multiple foci turn into a big and single mass,
and this would again be considered uni-focal. Hence, the
cumulative size or volume of the tumor is likely to be the
best predictor of malignant progression.
4 Conclusions
In conclusion, we suggest that the balance between tumor
promoting and inhibiting factors might be an important
driving force which determines the pattern on cancer pro-
gression, and can account for the occurrence of multi-
focal cancers. The best worked out example of such pro-
moter-inhibitor dynamics is angiogenesis. In this context,
inhibitors are produced both by healthy tissue cells and
by tumor cells. During the course of progression, tumor
cells can mutate and evolve to produce less inhibitors and
more promoters. The initial establishment of an ang-
iogenic cell line is the most difficult step. Since the pro-
moting factors are produced by angiogenic cells
themselves, their initial abundance has to be sufficiently
high, such that the balance can be shifted away from inhi-
bition. This enables the population of cancer cells to
expand beyond a very small size. This growth can then
give rise to a self-limited uni-focal cancer which can bifur-
cate to give rise to multi-focal cancers. Further evolution-
ary events can finally lead to maximal tissue invasion. If
the initial mutation allows the cells to sufficiently escape
from inhibition, cancer progression can occur as a single
expanding mass without the occurrence of multi-focality.
These arguments not only apply to angiogenesis, but to
any tumor promoting and inhibiting factors where
inhibitors act over a long range while promoters act
locally. Therefore, the therapeutic use of inhibitors should
be further explored. This is an active area of research in the
context of angiogenesis [30], and the identification of
possible alternative inhibitors might open new avenues of
investigation in this context.
5 Materials and Methods
Here we present mathematical methodology used to ana-
lyze the equations described in the text.
Linear stability analysis of the ODEs
Here we discuss a linear stability analysis of system (1–3).
Let us first simplify the problem by using a quasistation-
ary approach, that is, we will assume that the level of pro-
moters adjusts instantaneously to its steady-state value (P
= CaP/bP). It is convenient to denoteJournal of Carcinogenesis 2004, 3:13 http://www.carcinogenesis.com/content/3/1/13
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Now we have a two-dimensional system,
For simplicity we ignore the constant input term, ξ, which
describes the production of inhibitors by healthy tissue.
Numerical simulations have shown that results are not
altered qualitatively by this simplification.
There can be up to three fixed points in this system,
where ,  and
It is obvious that if γ + ε - W < 0, and (γ + ε - W)2 - 4εγ > 0,
then there are exactly three positive equilibria in the sys-
tem. If either of these conditions is violated, the (0,0)
solution is the only (biologically meaningful) stable
point.
Stability analysis can be performed by the usual methods.
For the (0,0) equilibrium, the Jacobian is
that is, this equilibrium is always stable. For the points
(C±, I±), we get the following Jacobian,
where we denote for convenience,
. It is easy to show that the
eigenvalues of this matrix for the solution ( ) are
given by
and for the solution ( ) we have eigenvalues
where Y ± ≡ 2bIW + δ(ε - γ - W ± Γ). We can see that solu-
tion ( ) is always unstable and we will not consider
it any longer. Solution ( ), which we call for simplic-
ity ( ) from now on, is stable as long as
Y+ > 0   (9)
Turing stability analysis
Here we present a linear analysis of system (4–6). As
before, we are going to assume that promoters adjust
instantaneously to their equilibrium level. By replacing P
with C defined by  , we can rewrite equation (4)
as
This equation together with equation (6) gives a Turing
model.
Let us go back to the system of ODEs, (7–8), and assume
that solution ( ) is a stable equilibrium. Of course, this
solution also satisfies the system of PDEs, (10,6). Let us
consider a wave-like deviation from this spatially uniform
solution:
Here, the amplitudes of the perturbation, A and B, are
small compared to the amplitude of the spatially uniform
solution, and we assume an infinitely large space. The
equation for the new eigenvalue, λ is
where we define
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Equation (11) can be written as
λ2 + λ(bI - α + (DC + DI)ω2) + aIβ - (bI + DIω2)(α - DCω2) =
0.   (12)
This is the dispersion relation which connects the growth-
rate, λ, with the spatial frequency of the perturbation, ω.
The stability conditions now are given by
bI - α + (DC + DI)ω2 > 0,   (13)
aIβ - (bI + DIω2)(α - DCω2) > 0.   (14)
Note that the stability conditions for solution ( ) of
the system of ODEs, (7–8), are obtained automatically
from the conditions above by setting ω = 0:
bI - α > 0,   (15)
aIβ - bI α > 0.   (16)
Inequality (13) is always satisfied because of inequality
(15). Let us derive conditions under which the spatially
uniform solution is unstable. This requires that condition
(14) is reversed. This can be expressed as follows:
F(ω) ≡ DIDCω4 - ω2γ1 + γ2 < 0.   (17)
where we denoted for simplicity,
γ1 = αDI - bIDC, γ2 = αIβ - αbI > 0.
This is a fourth order polynomial, symmetrical with
respect to the line ω = 0, with a positive leading term. The
points, ±|ω|, satisfying
correspond to the two minima of the left hand side of ine-
quality (17). Let us call these values of ω, ±ωc. The condi-
tion F(ωc) < 0 defines that the uniform solution ( ) is
unstable.
Let us plot the function F(ω) for different values of aI, see
Figure 5. For small values of aI, F(ω) is strictly positive,
and the spatially uniform solution is stable. As aI
increases, the function F(ω) crosses the line F = 0. The crit-
ical value of aI, aI,c, for which F(ωc) = 0, is determined
from
(αDI - bIDC)2 = 4DIDC(aIβ - αbI),
where α and β both depend on aI. We solved this equation
numerically to find the critical value of aI,c, see Figure 5.
The applicability of the above analysis depends on the
parameters of the system. First of all, we need conditions
(15–16) to be satisfied. They mean that without diffusion,
a positive, spatially uniform solution is stable. Next, we
need to be in a weakly nonlinear regime, where the function
F(ω) has only very narrow regions of ω corresponding to
negative values. More precisely, ∆ω ~ L-1, where L is the
spatial dimension of the system. In terms of parameter aI,
we require that it is sufficiently close to aI,c. Then, we can
calculate the "most unstable" wavenumber, that is, ωc
defined by equation (18), with aI,c. This value will deter-
mine the spatial period of the solution,
Stationary periodic solutions
In numerical simulations described in this paper, we used
the following (Neumann) boundary conditions:
The simulation results are presented in the main body of
the paper. Here we discuss the behavior of the system in
the light of the analysis presented above. Let us assume
that the value aI is below the critical, aI <aI,c. The system
exhibits bistability. If we start in the vicinity of a (0,0)
solution, then cancer will not grow and decay to zero. If
we start from a point (C, I) in the domain of attraction of
the solution ( ), then the system will develop towards
this positive spatially homogeneous stationary solution.
Next, let us suppose we have aI >aI,c, but make sure that it
is sufficiently close to aI,c (the exact meaning of "close" is
specified in the analysis above). Again, if the initial condi-
tions are close to the zero solution, then the zero state will
be the state that the system will attain. However, if we start
in the vicinity of the ( ) state, we will observe interest-
ing behavior. Solution ( ) is now unstable, and we will
see "ripples" developing on top of this solution. This is
Turing instability. The spatial period of the ripple was cal-
culated in the previous section. Long-time evolution of
this state is of course not in the realm of linear stability
analysis, but we can predict that the spatial scale of the
resulting solution will be given by (19).
Finally, let us assume that aI is much higher than critical.
Now, solution ( ) is unstable even in the system of
ODEs. However, a periodic solution will develop, unless
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the initial condition is in the domain of attraction of the
zero solution. The spatial scale of the periodic solution is
determined intrinsically by the parameters of the system,
and it grows with aI. Intuitively this is easy to understand,
because higher values of aI correspond to higher levels of
inhibition, so the distance between regions of large C will
become larger. Note that the exact period of the periodic
solution is adjusted to fit the boundary conditions of the
system. For instance, with the Neumann boundary condi-
tions, the boundary points are forced to be troughs of the
wave-like pattern. In other words, the period of the solu-
tion must be an integer fraction of L.
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